Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the veterans health administration

Diabetes Care

Volumn 30, Issue 7, 2007, Pages 1689-1693

  Kahler, Kristijan H ^a,d   Rajan, Mangala ^a   Rhoads, George G ^b   Safford, Monika M ^c   Demissie, Kitaw ^b   Lu, Shou En ^b   Pogach, Leonard M ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DIABETES MELLITUS; DRUG EFFECT; FEMALE; HEALTH CARE MANAGEMENT; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; SCORING SYSTEM; TREATMENT OUTCOME; VETERAN;

ADMINISTRATION, ORAL; AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALS, VETERANS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 34447117471     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-2272     Document Type: Article

References (23)

1. U.K. Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
2. U.K. Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
3. American Diabetes Association: Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 24 (Suppl. 1):S28-S32, 2002
4. Olsson J, Lindberg G, Gottsater M, Lindwall K, Sjostrand A, Tisell A, Melander A: Increased mortality in type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 43:558-560, 2000
5. Mannucci E, Monami M, Masotti G, Marchionni N: All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides. Diabetes Metab Res Rev 20:44-47, 2004
6. Fisman EZ, Tenenbaum A, Boyko V, Benderly M, Adler Y, Friedensohn A, Kohanovski M, Rotzak R, Schneider H, Behar S, Motro M: Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol 24:151-158, 2001
7. Johnson JA, Majumdar SR, Simpson SH, Toth EL: Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25:2244-2248, 2002
8. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA: Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 28:2345-2351, 2005
9. Miller DR, Safford MM, Pogach LM: Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data. Diabetes Care 27 (Suppl. 2):B10-B21, 2004
10. Weinstock RS, Hawley G, Repke D, Feuerstein BL, Sawin CT, Pogach LM: Pharmacy costs and glycemic control in the Department of Veterans Affairs. Diabetes Care 27 (Suppl. 2):B74-B81, 2004
11. Kazis LE, Perlin JB, Skinner KM, Ren XS, Lee A, Rogers W, Spiro A III, Selim A, Miller DR: Large Health Survey of Veteran Enrollees: Health Status and Outcomes of Veterans. Veterans SF-36 Physical and Mental Component Summary Scores, Executive Report, 2000. Washington, DC, Department of Veterans Affairs, Veterans Health Administration, Office of Quality and Performance, 1999
12. Little RR, Rohlfing CL, Wiedmeyer HM, Myers GL, Sacks DB, Goldstein DE: The national glycohemoglobin standardization program: a five-year progress report. Clin Chem 47:1985-1992, 2001
13. Breslow NE, Clayton DG: Approximate inference in generalized linear mixed models. J Am Stat Assoc 88:9-25, 1993
14. McCullagh P, Nelder JA: Generalized Linear Models. London, Chapman and Hall, 1989
15. Rubin DB: Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127:757-763, 1997
16. Perkins SM, Tu W, Underhill MG, Zhou X, Murray MD: The use of propensity scores in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf 9:93-101, 2000
17. Rubin DB: Inference and missing data. Biometrika 63:581-592, 1976
18. Hosmer DW, Lemeshow S: Applied Logistic Regression. New York, John Wiley & Sons, 2000
19. Turner RC, Holman RR: Metformin and risk of cardiovascular disease. Cardiology 91:203-204, 1999
20. Johnson JA, Simpson SH, Toth EL, Majumdar SR: Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabet Med 22:497-502, 2005
21. Kashner TM: Agreement between administrative files and written medical records: a case of the Department of Veterans Affairs. Med Care 36:1324-1336, 1998
22. Kerr EA, Smith DM, Hogan MM, Krein SL, Pogach L, Hofer TP, Hayward RA: Comparing clinical automated, medical record, and hybrid data sources for diabetes quality measures. Jt Comm J Qual Improv 28:555-565, 2002
23. Cowper DC, Kubal JD, Maynard C, Hynes DM: A primer and comparative review of major US mortality databases. Ann Epidemiol 12:462-468, 2002